← back to search

Fabienne Portales

CEA Valduc · FR
Area of research
Oncology · Cancer Research
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, and Cancer Treatment and Pharmacology.
h-index
19
citations
1,839
works
67
NIH funding
—
primary concept
Medicine
email
fabienne.portales@icm.unicancer.fr

Recent publications

Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)
Journal of Clinical Oncology 2025cited by 22position: middledoi
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Journal of Clinical Oncology 2022cited by 34position: middledoi
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Journal of Clinical Oncology 2020cited by 427position: middledoi
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
˜The œLancet. Gastroenterology & hepatology 2020cited by 242position: middledoi
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
ESMO Open 2020cited by 46position: middledoi
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
European Journal of Cancer 2017cited by 99position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Julien Taı̈eb · Assistance Publique – Hôpitaux de Paris2 papers (2020–2022)Jean‐Baptiste Bachet · Sorbonne Université2 papers (2020–2022)Pascal Hammel · Hôpital Broussais2 papers (2020–2022)Eric Van Cutsem · KU Leuven2 papers (2017–2020)— · 1 papers (2017–2017)Thomas Nydam · Novartis (Switzerland)1 papers (2020–2020)Philip A. Philip · Henry Ford Health System1 papers (2020–2020)Alfredo Falcone · Azienda ospedaliera "Bianchi-Melacrino-Morelli"1 papers (2020–2020)Daniel López‐Trabada · Hôpital Saint-Antoine1 papers (2020–2020)Roberto Pazo-Cid · Instituto de Salud Carlos III1 papers (2020–2020)— · 1 papers (2020–2020)Robert Winkler · Goethe University Frankfurt1 papers (2017–2017)Jamil Asselah · McGill University Health Centre1 papers (2020–2020)Loïck Vidot · Institut de Relations Internationales et Stratégiques1 papers (2020–2020)Guillaume Piessen · Institut Paoli-Calmettes1 papers (2022–2022)— · 1 papers (2017–2017)Patrick J. Loehrer · Yale Cancer Center1 papers (2017–2017)Christophe Borg · GERCOR (France)1 papers (2020–2020)Atsushi Ohtsu · National Cancer Center Hospital East1 papers (2017–2017)Salvatore Siena · Metropolitana Milanese (Italy)1 papers (2017–2017)